Oral Health in Africa: Promoting Collaborative Solutions

By Crystal Lubbe

April 1, 2025

oral health Africa

Is oral health taking a back seat in public health discussions in Africa? This article brings to the forefront the pressing challenges confronting oral health across the continent. Specifically, it highlights the widespread prevalence of untreated dental diseases and the critical shortage of oral health professionals—with the number of dentists ranging from just 1.77 to as few as 0.03 per 10,000 people. Consequently, millions continue to suffer from a high burden of untreated oral conditions, including dental caries, periodontal disease, oral cancers, HIV-related complications, and noma, all of which severely compromise quality of life.

Key Insights:

  • Oral Disease Burden: Untreated dental caries and periodontal disease are widespread in Africa. Regional variations are influenced by socioeconomic and dietary factors.
  • Workforce and Policy Gaps: Many countries face a critical shortage of dentists and dental care assistants. Inadequate oral health policies worsen the problem.
  • Collaborative Solutions: Partnerships among healthcare providers, industry, civil society, and academia are key to improving oral health outcomes.
  • Prevalence of Oral disease: Untreated caries (5+ years) is highest in Northern Africa (33.72%), severe periodontal disease (15+ years) in Western Africa (26.75%), and new lip and oral cavity cancer cases in Northern Africa (median: 269.5 cases). See Table 1 for details.
Table 1: Burden of major oral diseases in Africa (Foláyan et al 2015)

Background Context:

WHO reports Africa has seen the largest global rise in oral diseases over 30 years. Nearly 44% of the population is affected. Only 57% of African countries have a national oral health policy. The region spends less than US$1 per person annually on oral health. WHO’s Global Oral Health Strategy aims for universal coverage by 2030, focusing on prevention and community-based interventions.

Implications:

  • Health Economics: Oral diseases cause significant economic losses due to healthcare costs and lost productivity. Prevention and better care access can bring long-term benefits.
  • Health Outcomes: Integrating oral health into primary healthcare and community interventions can improve overall well-being.
  • Policy and Research: Strengthening local research is vital for evidence-based policies.

To address these issues effectively, stakeholders must take coordinated action. In particular, integrating oral health into national public health policies remains essential for expanding access to care. Furthermore, national dental associations, working in partnership with public health institutions and international organisations, can drive meaningful policy change and promote better resource allocation. Through such collaborative efforts, Africa can begin to close the oral health gap and deliver improved outcomes for its population. For more details, see the original article.

 

Reference url

Recent Posts

pharmaceutical access initiative
Pharmaceutical Access Initiative Promotes Unified Health Systems in Europe

By João L. Carapinha

June 12, 2026

The pharmaceutical access initiative led by the Beneluxa countries urges EU and EEA Member States to pursue closer coordination on medicine affordability and supply security. By combining forces, nations can protect universal health systems that treat healthcare as a social right while still enco...
health economic security
Health Economic Security as a Pillar for Growth in Central and Eastern Europe

By HEOR Staff Writer

June 12, 2026

Central and Eastern European nations face intensifying demographic pressures, including rapid population aging, shrinking workforces, and heightened security risks that endanger long-term prosperity. In a recent EFPIA statement, health economic security is seen as essential, as targeted healthcar...
Dutch Medicine Access Delay
Dutch Medicine Access Delay Impact on Patient Care in the Netherlands

By João L. Carapinha

June 10, 2026

Dutch Medicine Access Delay leaves patients in the Netherlands waiting far longer for innovative drugs than those in Germany. Of 51 treatments currently held in the Dutch assessment pathway, 48 are already on the market across the border, revealing a persistent structural lag driven by mandatory ...